Bypassing its standard pathways for scientific discussions, FDA has recently held a slew of so-called "expert panels" that sidestep legal procedures and ethics guardrails, raising concern about cherry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback